Flubendazole

Parasitic infections are a long-term challenge in the global public health sector, and there has been a long-standing clinical medication demand especially for the prevention and control of zoonotic helminthiasis. Flubendazole is a broad-spectrum benzimidazole antiparasitic drug. It inhibits the polymerization of parasite tubulin, blocks the uptake and utilization of glucose by parasites, and ultimately leads to energy depletion and death of the worms. Clinically, it can be used to treat common intestinal parasitic infections in humans caused by pinworm, roundworm, hookworm, whipworm and other parasites. Meanwhile, it is an important variety of antiparasitic drugs in the livestock and poultry breeding field, and has application value covering both human and veterinary scenarios.

The global flubendazole market size is approximately USD 230 million, and the compound annual growth rate from 2023 to 2028 is expected to remain at 4.7%. The growth momentum mainly comes from the release of demand for parasitic disease prevention and control in developing regions and the expansion of livestock breeding scale. The current market presents a competitive pattern where original research manufacturers and generic pharmaceutical companies coexist. The market concentration of human preparations is relatively high, and the production capacity of veterinary APIs is mainly concentrated in regions with advantages in API production such as China and India. The flubendazole APIs supplied by domestic enterprises account for more than 60% of the global veterinary market supply.

The original research enterprise of flubendazole is Janssen Pharmaceutica N.V. in Belgium, with the original brand name Fluoromeb. The core compound patent expired globally in 1983. The main dosage form approved by the original research is tablet with a specification of 100mg, which has been included in the FDA Reference Listed Drug Catalog, and is also collected in major international pharmacopoeias such as the European Pharmacopoeia and the British Pharmacopoeia. At present, the flubendazole APIs of multiple domestic enterprises have obtained CDE registration numbers (A status), and various preparations such as human tablets and veterinary powders have been approved for marketing, which can meet the medication demands of domestic clinical and livestock fields. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for flubendazole API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully support the reference standard demands throughout the whole process of API R&D, quality research and registration declaration.